Trevi Therapeutics, Inc. TRVI Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $9.94M+60.5% | $6.19M-38.6% | $10.09M+7.4% | $9.39M+20.2% | $7.81M-16.3% | ||
| $4.97M+23.4% | $4.03M+5.1% | $3.83M-11.6% | $4.33M+18.4% | $3.66M+25.5% | ||
| $14.91M+45.9% | $10.22M-26.6% | $13.92M+1.4% | $13.72M+19.6% | $11.47M-6.3% | ||
| -$14.91M-45.9% | -$10.22M+26.6% | -$13.92M-1.4% | -$13.72M-19.6% | -$11.47M+6.3% | ||
| $1.7M-10.0% | $1.89M-10.1% | $2.1M+49.9% | $1.4M+25.1% | $1.12M+32.6% | ||
| -$13.21M-58.6% | -$8.33M+29.5% | -$11.82M+4.1% | -$12.32M-19.0% | -$10.35M+9.2% | ||
| -$20K-25.0% | -$16K-6.7% | -$15K+28.6% | -$21K-90.9% | -$11K— | ||
| -$13.19M-58.6% | -$8.32M+29.5% | -$11.8M+4.1% | -$12.3M-19.0% | -$10.34M+9.4% | ||
| -$0.09-50.0% | -$0.06+25.0% | -$0.08+11.1% | -$0.090.0% | -$0.09+18.2% | ||
| -$14.88M-46.0% | -$10.19M+26.6% | -$13.88M-1.4% | -$13.68M-19.7% | -$11.43M+6.3% | ||
| -$14.91M-45.9% | -$10.22M+26.6% | -$13.92M-1.4% | -$13.72M-19.6% | -$11.47M+6.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Trevi Therapeutics, Inc. profitable?
- Trevi Therapeutics, Inc. is not currently profitable: it reported a net loss of $45.6M over the trailing twelve months.
- What is Trevi Therapeutics, Inc.'s earnings per share?
- Trevi Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.32.
- Where does Trevi Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Trevi Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.